文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

来那度胺联合伊达比星与阿糖胞苷化疗治疗复发或难治性急性髓系白血病及高危骨髓增生异常综合征的I期研究

A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
PubMed 文献 · Am J Hematol · 2020-09-19

该I期研究纳入33例复发/难治性急性髓系白血病(30例)和高危骨髓增生异常综合征(3例)患者,采用3+3设计在三个剂量水平测试来那度胺联合阿糖胞苷/伊达比星挽救化疗。确定最大耐受剂量为剂量水平-1(来那度胺25 mg/d D1-21,阿糖胞苷1 g/m2 D5-8,伊达比星8 mg/m2 D5-7),总完全缓解/完全缓解伴计数不完全恢复率为56%,1年和2年总生存率分别为24%和10%。

要点

  • 最大耐受剂量为来那度胺25 mg/d D1-21联合阿糖胞苷1 g/m2 D5-8和伊达比星8 mg/m2 D5-7。
  • 33例中18例达到完全缓解(14例)或完全缓解伴计数不完全恢复(4例),总CR/CRi率56%。
  • 1年和2年总生存率分别为24%和10%;应答者中10/18接受异基因造血干细胞移植,1年OS为40%。

核心结论

  • 来那度胺联合阿糖胞苷/伊达比星方案在复发/难治性急性髓系白血病中具有临床活性。
  • 作者认为该方案应进一步在造血干细胞移植后复发患者中研究,并作为移植桥接治疗。

研究设计与样本

  • I期研究,采用3+3设计,共纳入33例患者(30例急性髓系白血病,3例高危骨髓增生异常综合征),在三个剂量水平治疗。
  • 临床试验注册号:NCT01132586。

主要发现

  • 8例患者出现剂量限制性毒性,其中4例为血液学剂量限制性毒性。
  • 最常见的非血液学严重不良事件为发热性中性粒细胞减少、皮疹、脓毒症和肾损伤。
  • 15/33(45%)患者能够接受预定的21天来那度胺治疗。
  • 18例患者达到完全缓解(n=14)或完全缓解伴计数不完全恢复(n=4),总CR/CRi率56%。
  • 1年和2年总生存率分别为24%和10%;应答者中10/18接受异基因造血干细胞移植,1年OS为40%。

关键数值与推荐

  • 最大耐受剂量为剂量水平-1:来那度胺25 mg/d D1-21,阿糖胞苷1 g/m2 D5-8,伊达比星8 mg/m2 D5-7。

临床怎么用

  • 作者认为该方案应进一步在造血干细胞移植后复发患者中研究,并作为移植桥接治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) have poor outcomes and hematopoietic cell transplantation (HCT) is the only curative treatment. New targeted therapies improved survival in select patients with specific mutations, however management of patients without these molecular alterations is an unmet need. We conducted a phase one study of lenalidomide in combination with cytarabine/idarubicin salvage chemotherapy in patients with R/R AML and high-risk myelodysplastic syndromes. A total of 33 patients were enrolled in the study (30 AML, 3 MDS), and treated at three dose levels with 3 + 3 design. Dose-limiting toxicity (DLT) was seen in eight patients, including four hematologic DLTs. The most commonly observed non-hematologic serious adverse events were febrile neutropenia, rash, sepsis and renal injury. Dose level -1, consisting of 25 mg/d lenalidomide D1-21, 1 g/m2 cytarabine D5-8, and 8 mg/m2 idarubicin D5-7 was determined to be the maximum tolerated dose. Note, 15/33 (45%) of patients were able to receive pre-planned 21 days of lenalidomide. Overall, 18 patients achieved complete remission (CR) (n = 14) or CR with incomplete count recovery (CRi) (n = 4) with total CR/CRi rate of 56%. The 1-year and 2-year overall survival (OS) were 24% and 10%, respectively. Among responders, 10/18 underwent allogeneic HCT and had a 1-year OS of 40%. There was no molecular pattern associated with response. These data demonstrate that the combination had clinical activity in R/R AML. This regimen should be further investigated for patients who relapsed after HCT, and as a bridge therapy to HCT. (ClinicalTrials.gov identifier: NCT01132586).

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Saygin C, Larkin K, Blachly JS, et al. A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol. 2020. PMID: 32777116. doi:10.1002/ajh.25958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。